Loading…
Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Study
Purpose The OsteoCool Tumor Ablation Post-Market Study (OPuS One) was a prospective, multi-national, single-arm study to investigate safety and effectiveness of radiofrequency ablation (RFA) for palliation of painful lytic bone metastases with 12 months of follow-up. RFA has demonstrated effective p...
Saved in:
| Published in: | Cardiovascular and interventional radiology 2023-05, Vol.46 (5), p.600-609 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c475t-280262b16d119c0e772fe589fda2102e0fdf14d4bea41b089d5ec5801ddf96843 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c475t-280262b16d119c0e772fe589fda2102e0fdf14d4bea41b089d5ec5801ddf96843 |
| container_end_page | 609 |
| container_issue | 5 |
| container_start_page | 600 |
| container_title | Cardiovascular and interventional radiology |
| container_volume | 46 |
| creator | Levy, Jason David, Elizabeth Hopkins, Thomas Morris, Jonathan Tran, Nam D. Farid, Hamed Massari, Francesco O’Connell, William G. Vogel, Alexander Gangi, Afshin Sunenshine, Peter Dixon, Robert Von der Höh, Nicolas Bagla, Sandeep |
| description | Purpose
The OsteoCool Tumor Ablation Post-Market Study (OPuS One) was a prospective, multi-national, single-arm study to investigate safety and effectiveness of radiofrequency ablation (RFA) for palliation of painful lytic bone metastases with 12 months of follow-up. RFA has demonstrated effective palliation of osseous metastases in small clinical studies with short-term follow-up; however, a long-term assessment with robust subject numbers is lacking.
Materials and Methods
Prospective assessments were conducted at Baseline, 3 days, 1 week, and 1, 3, 6, and 12-months. Pain and quality of life were measured prior to RFA and postoperatively using the Brief Pain Inventory, European Quality of Life—5 Dimension, and European Organization for Research and Treatment of Cancer Care Quality of Life Questionnaire for palliative care. Radiation, chemotherapy and opioid usage, and related adverse events were collected.
Results
206 subjects were treated with RFA at 15 institutions in OPuS One. Worst pain, average pain, pain interference and quality of life significantly improved at all visits starting 3 days post-RFA and sustained to 12 months (
P
|
| doi_str_mv | 10.1007/s00270-023-03417-x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10156864</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2808753863</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-280262b16d119c0e772fe589fda2102e0fdf14d4bea41b089d5ec5801ddf96843</originalsourceid><addsrcrecordid>eNp9ktFuFCEUhidGY7fVF_DCkHjjzSgwwwzjjalrq022abOuiXeEGQ5dKjOswGy6b-rjyHZqq16YEEjgO_9_gD_LXhD8hmBcvw0Y0xrnmBY5LkpS5zePshkpC5pjXn17nM0wqcucMEYOssMQrjEmjFP2NDsoakxo0dBZ9nMplXHaw48Rhm6Hjlsro3EDuvRuaxQEtJQbo5AcFPo4etlaQJfSDGgJ1oBG2nkU1_s9a02q3AJaeZCxhyEip9FiF02HPrgB0DlEGdJImmeDgg2kaYL2PUyuqzV4udm9Q6dmkDaZhNHGgLR3_a3NRYjg5s5ZtBr7ZP3QrgsxP5f-O0T0JY5q9yx7oqUN8PxuPcq-np6s5p_zxcWns_nxIu_KmsWcckwr2pJKEdJ0GOqaamC80UpSgilgrTQpVdmCLEmLeaMYdIxjopRuKl4WR9n7SXcztj2oLl3JSys23vTS74STRvx9Mpi1uHJbQdJvVLzaK7y-U_Au_UKIojehA2vlAG4MgtYNKxgvMU_oq3_Qazf69FKJ4pjXrOBVkSg6UZ13IXjQ990QLPbJEVNyREqOuE2OuElFL_-8x33J76gkoJiAkI6GK_AP3v-R_QU9p9Qh</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2808753863</pqid></control><display><type>article</type><title>Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Study</title><source>Springer Nature</source><creator>Levy, Jason ; David, Elizabeth ; Hopkins, Thomas ; Morris, Jonathan ; Tran, Nam D. ; Farid, Hamed ; Massari, Francesco ; O’Connell, William G. ; Vogel, Alexander ; Gangi, Afshin ; Sunenshine, Peter ; Dixon, Robert ; Von der Höh, Nicolas ; Bagla, Sandeep</creator><creatorcontrib>Levy, Jason ; David, Elizabeth ; Hopkins, Thomas ; Morris, Jonathan ; Tran, Nam D. ; Farid, Hamed ; Massari, Francesco ; O’Connell, William G. ; Vogel, Alexander ; Gangi, Afshin ; Sunenshine, Peter ; Dixon, Robert ; Von der Höh, Nicolas ; Bagla, Sandeep</creatorcontrib><description>Purpose
The OsteoCool Tumor Ablation Post-Market Study (OPuS One) was a prospective, multi-national, single-arm study to investigate safety and effectiveness of radiofrequency ablation (RFA) for palliation of painful lytic bone metastases with 12 months of follow-up. RFA has demonstrated effective palliation of osseous metastases in small clinical studies with short-term follow-up; however, a long-term assessment with robust subject numbers is lacking.
Materials and Methods
Prospective assessments were conducted at Baseline, 3 days, 1 week, and 1, 3, 6, and 12-months. Pain and quality of life were measured prior to RFA and postoperatively using the Brief Pain Inventory, European Quality of Life—5 Dimension, and European Organization for Research and Treatment of Cancer Care Quality of Life Questionnaire for palliative care. Radiation, chemotherapy and opioid usage, and related adverse events were collected.
Results
206 subjects were treated with RFA at 15 institutions in OPuS One. Worst pain, average pain, pain interference and quality of life significantly improved at all visits starting 3 days post-RFA and sustained to 12 months (
P
< 0.0001). Post hoc analysis found neither systemic chemotherapy nor local radiation therapy at the index site of RFA influenced worst pain, average pain, or pain interference. Six subjects had device/procedure-related adverse events.
Conclusion
RFA for lytic metastases provides rapid (within 3 days) and statistically significant pain and quality of life improvements with sustained long-term relief through 12 months and a high degree of safety, independent of radiation.
Level of Evidence: 2b, Prospective, Non-Randomized, Post-Market study
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors
www.springer.com/00266
.</description><identifier>ISSN: 0174-1551</identifier><identifier>EISSN: 1432-086X</identifier><identifier>DOI: 10.1007/s00270-023-03417-x</identifier><identifier>PMID: 37012392</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Ablation ; Adverse events ; Bone Neoplasms - radiotherapy ; Bone Neoplasms - secondary ; Cardiology ; Catheter Ablation - methods ; Chemotherapy ; Clinical Investigation ; Humans ; Imaging ; Interference ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Non-Vascular Interventions ; Nuclear Medicine ; Pain ; Pain - surgery ; Palliation ; Palliative Care - methods ; Prospective Studies ; Quality of Life ; Radiation ; Radiation therapy ; Radio frequency ; Radiofrequency ablation ; Radiofrequency Ablation - methods ; Radiology ; Statistical analysis ; Treatment Outcome ; Tumors ; Ultrasound</subject><ispartof>Cardiovascular and interventional radiology, 2023-05, Vol.46 (5), p.600-609</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-280262b16d119c0e772fe589fda2102e0fdf14d4bea41b089d5ec5801ddf96843</citedby><cites>FETCH-LOGICAL-c475t-280262b16d119c0e772fe589fda2102e0fdf14d4bea41b089d5ec5801ddf96843</cites><orcidid>0000-0002-1272-5530</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37012392$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Levy, Jason</creatorcontrib><creatorcontrib>David, Elizabeth</creatorcontrib><creatorcontrib>Hopkins, Thomas</creatorcontrib><creatorcontrib>Morris, Jonathan</creatorcontrib><creatorcontrib>Tran, Nam D.</creatorcontrib><creatorcontrib>Farid, Hamed</creatorcontrib><creatorcontrib>Massari, Francesco</creatorcontrib><creatorcontrib>O’Connell, William G.</creatorcontrib><creatorcontrib>Vogel, Alexander</creatorcontrib><creatorcontrib>Gangi, Afshin</creatorcontrib><creatorcontrib>Sunenshine, Peter</creatorcontrib><creatorcontrib>Dixon, Robert</creatorcontrib><creatorcontrib>Von der Höh, Nicolas</creatorcontrib><creatorcontrib>Bagla, Sandeep</creatorcontrib><title>Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Study</title><title>Cardiovascular and interventional radiology</title><addtitle>Cardiovasc Intervent Radiol</addtitle><addtitle>Cardiovasc Intervent Radiol</addtitle><description>Purpose
The OsteoCool Tumor Ablation Post-Market Study (OPuS One) was a prospective, multi-national, single-arm study to investigate safety and effectiveness of radiofrequency ablation (RFA) for palliation of painful lytic bone metastases with 12 months of follow-up. RFA has demonstrated effective palliation of osseous metastases in small clinical studies with short-term follow-up; however, a long-term assessment with robust subject numbers is lacking.
Materials and Methods
Prospective assessments were conducted at Baseline, 3 days, 1 week, and 1, 3, 6, and 12-months. Pain and quality of life were measured prior to RFA and postoperatively using the Brief Pain Inventory, European Quality of Life—5 Dimension, and European Organization for Research and Treatment of Cancer Care Quality of Life Questionnaire for palliative care. Radiation, chemotherapy and opioid usage, and related adverse events were collected.
Results
206 subjects were treated with RFA at 15 institutions in OPuS One. Worst pain, average pain, pain interference and quality of life significantly improved at all visits starting 3 days post-RFA and sustained to 12 months (
P
< 0.0001). Post hoc analysis found neither systemic chemotherapy nor local radiation therapy at the index site of RFA influenced worst pain, average pain, or pain interference. Six subjects had device/procedure-related adverse events.
Conclusion
RFA for lytic metastases provides rapid (within 3 days) and statistically significant pain and quality of life improvements with sustained long-term relief through 12 months and a high degree of safety, independent of radiation.
Level of Evidence: 2b, Prospective, Non-Randomized, Post-Market study
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors
www.springer.com/00266
.</description><subject>Ablation</subject><subject>Adverse events</subject><subject>Bone Neoplasms - radiotherapy</subject><subject>Bone Neoplasms - secondary</subject><subject>Cardiology</subject><subject>Catheter Ablation - methods</subject><subject>Chemotherapy</subject><subject>Clinical Investigation</subject><subject>Humans</subject><subject>Imaging</subject><subject>Interference</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Non-Vascular Interventions</subject><subject>Nuclear Medicine</subject><subject>Pain</subject><subject>Pain - surgery</subject><subject>Palliation</subject><subject>Palliative Care - methods</subject><subject>Prospective Studies</subject><subject>Quality of Life</subject><subject>Radiation</subject><subject>Radiation therapy</subject><subject>Radio frequency</subject><subject>Radiofrequency ablation</subject><subject>Radiofrequency Ablation - methods</subject><subject>Radiology</subject><subject>Statistical analysis</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Ultrasound</subject><issn>0174-1551</issn><issn>1432-086X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9ktFuFCEUhidGY7fVF_DCkHjjzSgwwwzjjalrq022abOuiXeEGQ5dKjOswGy6b-rjyHZqq16YEEjgO_9_gD_LXhD8hmBcvw0Y0xrnmBY5LkpS5zePshkpC5pjXn17nM0wqcucMEYOssMQrjEmjFP2NDsoakxo0dBZ9nMplXHaw48Rhm6Hjlsro3EDuvRuaxQEtJQbo5AcFPo4etlaQJfSDGgJ1oBG2nkU1_s9a02q3AJaeZCxhyEip9FiF02HPrgB0DlEGdJImmeDgg2kaYL2PUyuqzV4udm9Q6dmkDaZhNHGgLR3_a3NRYjg5s5ZtBr7ZP3QrgsxP5f-O0T0JY5q9yx7oqUN8PxuPcq-np6s5p_zxcWns_nxIu_KmsWcckwr2pJKEdJ0GOqaamC80UpSgilgrTQpVdmCLEmLeaMYdIxjopRuKl4WR9n7SXcztj2oLl3JSys23vTS74STRvx9Mpi1uHJbQdJvVLzaK7y-U_Au_UKIojehA2vlAG4MgtYNKxgvMU_oq3_Qazf69FKJ4pjXrOBVkSg6UZ13IXjQ990QLPbJEVNyREqOuE2OuElFL_-8x33J76gkoJiAkI6GK_AP3v-R_QU9p9Qh</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>Levy, Jason</creator><creator>David, Elizabeth</creator><creator>Hopkins, Thomas</creator><creator>Morris, Jonathan</creator><creator>Tran, Nam D.</creator><creator>Farid, Hamed</creator><creator>Massari, Francesco</creator><creator>O’Connell, William G.</creator><creator>Vogel, Alexander</creator><creator>Gangi, Afshin</creator><creator>Sunenshine, Peter</creator><creator>Dixon, Robert</creator><creator>Von der Höh, Nicolas</creator><creator>Bagla, Sandeep</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1272-5530</orcidid></search><sort><creationdate>20230501</creationdate><title>Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Study</title><author>Levy, Jason ; David, Elizabeth ; Hopkins, Thomas ; Morris, Jonathan ; Tran, Nam D. ; Farid, Hamed ; Massari, Francesco ; O’Connell, William G. ; Vogel, Alexander ; Gangi, Afshin ; Sunenshine, Peter ; Dixon, Robert ; Von der Höh, Nicolas ; Bagla, Sandeep</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-280262b16d119c0e772fe589fda2102e0fdf14d4bea41b089d5ec5801ddf96843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Ablation</topic><topic>Adverse events</topic><topic>Bone Neoplasms - radiotherapy</topic><topic>Bone Neoplasms - secondary</topic><topic>Cardiology</topic><topic>Catheter Ablation - methods</topic><topic>Chemotherapy</topic><topic>Clinical Investigation</topic><topic>Humans</topic><topic>Imaging</topic><topic>Interference</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Non-Vascular Interventions</topic><topic>Nuclear Medicine</topic><topic>Pain</topic><topic>Pain - surgery</topic><topic>Palliation</topic><topic>Palliative Care - methods</topic><topic>Prospective Studies</topic><topic>Quality of Life</topic><topic>Radiation</topic><topic>Radiation therapy</topic><topic>Radio frequency</topic><topic>Radiofrequency ablation</topic><topic>Radiofrequency Ablation - methods</topic><topic>Radiology</topic><topic>Statistical analysis</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Ultrasound</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Levy, Jason</creatorcontrib><creatorcontrib>David, Elizabeth</creatorcontrib><creatorcontrib>Hopkins, Thomas</creatorcontrib><creatorcontrib>Morris, Jonathan</creatorcontrib><creatorcontrib>Tran, Nam D.</creatorcontrib><creatorcontrib>Farid, Hamed</creatorcontrib><creatorcontrib>Massari, Francesco</creatorcontrib><creatorcontrib>O’Connell, William G.</creatorcontrib><creatorcontrib>Vogel, Alexander</creatorcontrib><creatorcontrib>Gangi, Afshin</creatorcontrib><creatorcontrib>Sunenshine, Peter</creatorcontrib><creatorcontrib>Dixon, Robert</creatorcontrib><creatorcontrib>Von der Höh, Nicolas</creatorcontrib><creatorcontrib>Bagla, Sandeep</creatorcontrib><collection>SpringerOpen website</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Source</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cardiovascular and interventional radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Levy, Jason</au><au>David, Elizabeth</au><au>Hopkins, Thomas</au><au>Morris, Jonathan</au><au>Tran, Nam D.</au><au>Farid, Hamed</au><au>Massari, Francesco</au><au>O’Connell, William G.</au><au>Vogel, Alexander</au><au>Gangi, Afshin</au><au>Sunenshine, Peter</au><au>Dixon, Robert</au><au>Von der Höh, Nicolas</au><au>Bagla, Sandeep</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Study</atitle><jtitle>Cardiovascular and interventional radiology</jtitle><stitle>Cardiovasc Intervent Radiol</stitle><addtitle>Cardiovasc Intervent Radiol</addtitle><date>2023-05-01</date><risdate>2023</risdate><volume>46</volume><issue>5</issue><spage>600</spage><epage>609</epage><pages>600-609</pages><issn>0174-1551</issn><eissn>1432-086X</eissn><abstract>Purpose
The OsteoCool Tumor Ablation Post-Market Study (OPuS One) was a prospective, multi-national, single-arm study to investigate safety and effectiveness of radiofrequency ablation (RFA) for palliation of painful lytic bone metastases with 12 months of follow-up. RFA has demonstrated effective palliation of osseous metastases in small clinical studies with short-term follow-up; however, a long-term assessment with robust subject numbers is lacking.
Materials and Methods
Prospective assessments were conducted at Baseline, 3 days, 1 week, and 1, 3, 6, and 12-months. Pain and quality of life were measured prior to RFA and postoperatively using the Brief Pain Inventory, European Quality of Life—5 Dimension, and European Organization for Research and Treatment of Cancer Care Quality of Life Questionnaire for palliative care. Radiation, chemotherapy and opioid usage, and related adverse events were collected.
Results
206 subjects were treated with RFA at 15 institutions in OPuS One. Worst pain, average pain, pain interference and quality of life significantly improved at all visits starting 3 days post-RFA and sustained to 12 months (
P
< 0.0001). Post hoc analysis found neither systemic chemotherapy nor local radiation therapy at the index site of RFA influenced worst pain, average pain, or pain interference. Six subjects had device/procedure-related adverse events.
Conclusion
RFA for lytic metastases provides rapid (within 3 days) and statistically significant pain and quality of life improvements with sustained long-term relief through 12 months and a high degree of safety, independent of radiation.
Level of Evidence: 2b, Prospective, Non-Randomized, Post-Market study
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors
www.springer.com/00266
.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>37012392</pmid><doi>10.1007/s00270-023-03417-x</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-1272-5530</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0174-1551 |
| ispartof | Cardiovascular and interventional radiology, 2023-05, Vol.46 (5), p.600-609 |
| issn | 0174-1551 1432-086X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10156864 |
| source | Springer Nature |
| subjects | Ablation Adverse events Bone Neoplasms - radiotherapy Bone Neoplasms - secondary Cardiology Catheter Ablation - methods Chemotherapy Clinical Investigation Humans Imaging Interference Medicine Medicine & Public Health Metastases Metastasis Non-Vascular Interventions Nuclear Medicine Pain Pain - surgery Palliation Palliative Care - methods Prospective Studies Quality of Life Radiation Radiation therapy Radio frequency Radiofrequency ablation Radiofrequency Ablation - methods Radiology Statistical analysis Treatment Outcome Tumors Ultrasound |
| title | Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A28%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiofrequency%20Ablation%20Provides%20Rapid%20and%20Durable%20Pain%20Relief%20for%20the%20Palliative%20Treatment%20of%20Lytic%20Bone%20Metastases%20Independent%20of%20Radiation%20Therapy:%20Final%20Results%20from%20the%20OsteoCool%20Tumor%20Ablation%20Post-Market%20Study&rft.jtitle=Cardiovascular%20and%20interventional%20radiology&rft.au=Levy,%20Jason&rft.date=2023-05-01&rft.volume=46&rft.issue=5&rft.spage=600&rft.epage=609&rft.pages=600-609&rft.issn=0174-1551&rft.eissn=1432-086X&rft_id=info:doi/10.1007/s00270-023-03417-x&rft_dat=%3Cproquest_pubme%3E2808753863%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c475t-280262b16d119c0e772fe589fda2102e0fdf14d4bea41b089d5ec5801ddf96843%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2808753863&rft_id=info:pmid/37012392&rfr_iscdi=true |